 Jeffrey Sawyer
Concepts (159)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosomes, Human, Pair 1 | 8 | 2019 | 113 | 2.410 |
Why?
| | Multiple Myeloma | 20 | 2024 | 3049 | 1.550 |
Why?
| | Translocation, Genetic | 6 | 2019 | 287 | 1.400 |
Why?
| | Orthopedics | 3 | 2022 | 53 | 1.130 |
Why?
| | Fractures, Open | 1 | 2022 | 8 | 0.840 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 88 | 0.770 |
Why?
| | Chromosomal Instability | 1 | 2019 | 17 | 0.710 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 185 | 0.710 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 302 | 0.650 |
Why?
| | Pediatrics | 1 | 2021 | 324 | 0.620 |
Why?
| | Gene Amplification | 2 | 2019 | 57 | 0.530 |
Why?
| | Heterochromatin | 2 | 2009 | 6 | 0.520 |
Why?
| | Gene Dosage | 1 | 2015 | 92 | 0.510 |
Why?
| | Chromosome Deletion | 2 | 2017 | 150 | 0.490 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2014 | 43 | 0.470 |
Why?
| | Scoliosis | 2 | 2023 | 58 | 0.420 |
Why?
| | Melphalan | 2 | 2016 | 184 | 0.420 |
Why?
| | Myelodysplastic Syndromes | 2 | 2013 | 79 | 0.410 |
Why?
| | Chromosome Aberrations | 5 | 2016 | 316 | 0.400 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2019 | 278 | 0.370 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 485 | 0.320 |
Why?
| | Myeloablative Agonists | 1 | 2007 | 33 | 0.310 |
Why?
| | Prognosis | 8 | 2021 | 2126 | 0.310 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2007 | 61 | 0.300 |
Why?
| | Humans | 29 | 2024 | 54304 | 0.300 |
Why?
| | Child | 6 | 2022 | 7372 | 0.250 |
Why?
| | Disease Progression | 3 | 2019 | 915 | 0.250 |
Why?
| | Bone Marrow | 3 | 2022 | 414 | 0.240 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 167 | 0.230 |
Why?
| | Cytogenetic Analysis | 2 | 2014 | 90 | 0.220 |
Why?
| | Clubfoot | 1 | 2022 | 2 | 0.210 |
Why?
| | Spinal Fusion | 1 | 2023 | 71 | 0.210 |
Why?
| | Foot Orthoses | 1 | 2022 | 7 | 0.210 |
Why?
| | Radiologic Health | 1 | 2021 | 2 | 0.200 |
Why?
| | Risk Adjustment | 1 | 2021 | 27 | 0.200 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2021 | 8 | 0.200 |
Why?
| | Mutation | 2 | 2020 | 1504 | 0.190 |
Why?
| | Fasting | 1 | 2020 | 76 | 0.190 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2016 | 868 | 0.190 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 82 | 0.180 |
Why?
| | Research Design | 1 | 2022 | 356 | 0.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 92 | 0.170 |
Why?
| | Follow-Up Studies | 5 | 2024 | 2389 | 0.170 |
Why?
| | Karyotyping | 3 | 2017 | 92 | 0.170 |
Why?
| | Syndrome | 1 | 2019 | 253 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1060 | 0.160 |
Why?
| | Karyotype | 2 | 2017 | 19 | 0.160 |
Why?
| | Retrospective Studies | 4 | 2023 | 6462 | 0.150 |
Why?
| | Chromosome Disorders | 1 | 2017 | 39 | 0.150 |
Why?
| | Genetic Association Studies | 1 | 2017 | 136 | 0.150 |
Why?
| | Thalidomide | 2 | 2016 | 398 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 583 | 0.140 |
Why?
| | Gene Expression Profiling | 6 | 2014 | 1141 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 825 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 1222 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 564 | 0.130 |
Why?
| | Genome, Human | 1 | 2015 | 131 | 0.130 |
Why?
| | Alleles | 1 | 2015 | 277 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 645 | 0.120 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2014 | 10 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 571 | 0.120 |
Why?
| | Gene Fusion | 2 | 2014 | 14 | 0.120 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 76 | 0.120 |
Why?
| | Metaphase | 2 | 2016 | 55 | 0.110 |
Why?
| | Bone Marrow Cells | 1 | 2014 | 232 | 0.110 |
Why?
| | Risk | 1 | 2014 | 343 | 0.110 |
Why?
| | Aged | 8 | 2022 | 10054 | 0.110 |
Why?
| | Leukemia | 1 | 2013 | 69 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 399 | 0.100 |
Why?
| | Transcription Factors | 1 | 2015 | 622 | 0.100 |
Why?
| | Observer Variation | 2 | 2022 | 139 | 0.100 |
Why?
| | DNA Methylation | 1 | 2015 | 575 | 0.100 |
Why?
| | Chromosome Breakage | 1 | 2009 | 19 | 0.090 |
Why?
| | Survival Rate | 3 | 2020 | 954 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2022 | 1294 | 0.090 |
Why?
| | Female | 9 | 2022 | 28457 | 0.080 |
Why?
| | Age Distribution | 1 | 2007 | 198 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2019 | 488 | 0.070 |
Why?
| | Neoplasms | 1 | 2017 | 1321 | 0.070 |
Why?
| | Male | 8 | 2022 | 27335 | 0.070 |
Why?
| | Prospective Studies | 2 | 2016 | 2604 | 0.070 |
Why?
| | Chromosome Banding | 1 | 2006 | 28 | 0.070 |
Why?
| | Middle Aged | 5 | 2021 | 13076 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 514 | 0.070 |
Why?
| | Models, Genetic | 1 | 2006 | 208 | 0.070 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 192 | 0.070 |
Why?
| | Paraproteinemias | 1 | 2006 | 80 | 0.070 |
Why?
| | Risk Factors | 3 | 2013 | 3934 | 0.070 |
Why?
| | Cyclin D1 | 1 | 2005 | 60 | 0.060 |
Why?
| | Adult | 5 | 2020 | 14189 | 0.060 |
Why?
| | Databases, Factual | 1 | 2007 | 683 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1044 | 0.060 |
Why?
| | Survival Analysis | 2 | 2021 | 736 | 0.060 |
Why?
| | Expert Testimony | 1 | 2022 | 13 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2022 | 5609 | 0.060 |
Why?
| | Morphine | 1 | 2023 | 95 | 0.050 |
Why?
| | Braces | 1 | 2022 | 10 | 0.050 |
Why?
| | Analgesics | 1 | 2023 | 107 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2023 | 160 | 0.050 |
Why?
| | Consensus | 1 | 2022 | 156 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 435 | 0.050 |
Why?
| | Epiphyses | 1 | 2021 | 7 | 0.050 |
Why?
| | Arkansas | 1 | 2007 | 2097 | 0.050 |
Why?
| | Hunger | 1 | 2020 | 22 | 0.050 |
Why?
| | Lower Extremity | 1 | 2022 | 103 | 0.050 |
Why?
| | Conscious Sedation | 1 | 2020 | 28 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 275 | 0.050 |
Why?
| | Patient Compliance | 1 | 2022 | 247 | 0.050 |
Why?
| | Radiography | 1 | 2021 | 526 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 820 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 217 | 0.040 |
Why?
| | Centromere | 1 | 1998 | 17 | 0.040 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2017 | 42 | 0.040 |
Why?
| | Adolescent | 2 | 2023 | 6896 | 0.040 |
Why?
| | Genetic Testing | 1 | 2017 | 135 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 540 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2006 | 175 | 0.030 |
Why?
| | Cyclins | 2 | 2006 | 54 | 0.030 |
Why?
| | Hepatocyte Growth Factor | 1 | 2015 | 14 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 357 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 1361 | 0.030 |
Why?
| | Binding Sites | 1 | 2015 | 440 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 360 | 0.030 |
Why?
| | Infant | 1 | 2022 | 3832 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 520 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 552 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2012 | 50 | 0.030 |
Why?
| | Boronic Acids | 1 | 2013 | 197 | 0.030 |
Why?
| | Pyrazines | 1 | 2013 | 203 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2012 | 85 | 0.030 |
Why?
| | Acute Disease | 1 | 2013 | 403 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2006 | 1203 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2012 | 195 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 1551 | 0.020 |
Why?
| | Models, Statistical | 1 | 2012 | 258 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1616 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 1083 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 922 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2012 | 1229 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 20 | 0.020 |
Why?
| | Syndecans | 1 | 2006 | 43 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 54 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2006 | 82 | 0.020 |
Why?
| | Proteoglycans | 1 | 2006 | 96 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2006 | 244 | 0.020 |
Why?
| | Cyclin D3 | 1 | 2005 | 6 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 173 | 0.020 |
Why?
| | Cyclin D2 | 1 | 2005 | 20 | 0.020 |
Why?
| | Trisomy | 1 | 2005 | 34 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 430 | 0.020 |
Why?
| | Recurrence | 1 | 2006 | 692 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 270 | 0.020 |
Why?
| | Plasma Cells | 1 | 2006 | 239 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 474 | 0.020 |
Why?
| | Bone Diseases | 1 | 2005 | 108 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 4313 | 0.010 |
Why?
| | Cohort Studies | 1 | 2006 | 1547 | 0.010 |
Why?
|
|
Sawyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|